Whole Genome and Exome Sequencing: Global Market Review 2021-2025 and Growth Outlook 2026-2031 Featuring Illumina, Thermo Fisher Scientific, BGI Genomi…

The market for whole genome and exome sequencing is set to grow significantly, driven by decreasing sequencing costs and a ...
Seeking Alpha

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication

Focus on Inborn Errors of Immunity expands access to exome and genome testing for the known 200,000+ patients in the US 1 impacted by these conditions and opens new opportunities for GeneDx and ...

GeneDx raises 2025 revenue guidance to $415M and exome/genome revenue growth to 52% while accelerating NICU and pediatric market expansion

Q2 2025 Management View Katherine A. Stueland, President and CEO, highlighted that GeneDx achieved a milestone by delivering over $100 million in quarterly revenue for the first time, describing it as ...
Nasdaq

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication

GeneDx Recognizes Cerebral Palsy Awareness Month with Commitment to Improve Access to Testing GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes ...
Seeking Alpha

GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program

Jaguar Gene Therapy joins as founding partner to initiate a genetic testing program for SHANK3-related autism spectrum disorder and Phelan-McDermid syndrome GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx ...
Business Wire

GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today its launch on Aura, Epic’s specialty diagnostics ...